Go Deep
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,154 | 3.8 | 4.53 | 0.42 | 186.90 |
| Oct 2026 | 22,558 | 3.8 | 4.48 | 0.42 | 184.85 |
Sun Pharma Advanced Research Company Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 399,200,000.0 | 18,532,200,000.0 | 84,500,000.0 | 78,600,000.0 |
| Net Profit | -207,800,000.0 | 17,613,400,000.0 | -804,200,000.0 | -758,500,000.0 |
| EPS | -0.6 | 54.3 | -2.5 | -2.3 |
Sun Pharma Advanced Research Company Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 391,483,000.0 | 717,660,000.0 | 755,453,000.0 | 2,387,801,000.0 | — |
| Net Profit | 15,532,043,000.0 | -3,425,094,000.0 | -3,872,139,000.0 | -2,225,835,000.0 | — |
| EPS | 47.9 | -10.6 | -11.9 | -7.8 | — |
Sun Pharma Advanced Research Company Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 21,708,762,000.0 | 3,355,335,000.0 | 5,150,422,000.0 | 8,301,261,000.0 | — |
| Total Liabilities | 8,320,490,000.0 | 5,524,815,000.0 | 3,892,868,000.0 | 3,173,510,000.0 | — |
| Total Equity | 13,388,272,000.0 | -2,169,480,000.0 | 1,257,554,000.0 | 5,127,751,000.0 | — |
Owes vs Owns
Sun Pharma Advanced Research Company Limited owed ₹0.38 for every ₹1 it owned in Mar 2026, about the same as ₹0.38 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.38× | 1.65× | 0.76× | 0.38× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sun Pharma Advanced Research Company Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Fixed assets (tangible) 3.9%Intangible assets 3.3%Long-term investments 1.3%Other assets 91.0%
How it's funded — Mar 2026
Short-term debt 25.6%Payables 4.5%Other liabilities 8.2%Shareholders' equity 61.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1.3 | 2.0 | 157.1 | 402.5 |
| Receivables | 8.3 | 16.1 | 15.5 | 32.7 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 85.7 | 99.3 | 109.0 | 109.0 |
| Intangible assets | 71.3 | 53.7 | 42.7 | 25.5 |
| Long-term investments | 28.7 | 26.1 | 25.5 | 150.0 |
| Other assets | 1,975.5 | 138.5 | 165.1 | 110.4 |
| Liabilities & equity | ||||
| Short-term debt | 556.1 | 158.2 | 47.0 | 0.1 |
| Long-term debt | 0.0 | 100.0 | 0.0 | 12.6 |
| Payables | 98.7 | 117.7 | 145.8 | 148.3 |
| Other liabilities | 177.2 | 176.6 | 196.5 | 156.4 |
| Shareholders' equity | 1,338.8 | -216.9 | 125.8 | 512.8 |
| Net tangible assets | 1,267.5 | -270.6 | 83.0 | 487.3 |
Sun Pharma Advanced Research Company Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -2,387,768,000.0 | -3,602,931,000.0 | -4,291,883,000.0 | -691,179,000.0 | — |
| Investing Activities | -234,964,000.0 | 1,576,600,000.0 | 3,915,271,000.0 | -5,482,780,000.0 | — |
| Financing Activities | 2,613,859,000.0 | 1,992,556,000.0 | 424,051,000.0 | 6,167,553,000.0 | — |